Nplate, Romiplate (romiplostim) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Nplate, Romiplate (romiplostim) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historical period can be attributed to the rising prevalence of immune thrombocytopenic purpura, increasing regulatory approvals, growing awareness of health and diagnostics, the expansion of clinical research institutions, and enhanced patient support programs.

The anticipated growth during the forecast period is driven by factors such as expanding global healthcare access, improving health economics, innovations in biotechnology, more effective treatments, and a rising incidence of blood disorders. Key trends for the forecast period include the emergence of biosimilars, advancements in treatment protocols, technology integration, new drug delivery methods, strategic collaborations, and increased investments in research and development.

The increasing incidence of cancer is expected to propel the growth of the nplate, romiplate (romiplostim) market. Cancer refers to a group of diseases characterized by the abnormal and uncontrolled growth of cells. The rise in cancer cases is attributed to factors such as an aging population, environmental exposure to carcinogens, unhealthy lifestyle choices (e.g., smoking, poor diet), genetic factors, and advancements in diagnostic techniques that lead to earlier and more frequent cancer detection. Nplate and Romiplate (Romiplostim) stimulate platelet production via the thrombopoietin receptor, which helps cancer patients - especially those undergoing chemotherapy - by reducing the risk of thrombocytopenia (low platelet counts), improving platelet levels, enhancing safety during treatment, and minimizing the need for platelet transfusions. For example, in August 2024, the Australian Institute of Health and Welfare projected that by 2034, Australia would see approximately 209,000 new cancer diagnoses, up from an estimated 169,000 in 2024, reflecting the impact of a growing population and increasing cancer rates. Thus, the rising cancer incidence will drive the nplate, romiplate (romiplostim) market.

Rising healthcare expenditure is expected to propel the growth of the nplate, romiplate (romiplostim) market. Healthcare expenditure refers to the total spending on healthcare goods and services, including personal health care, preventive services, and public health activities aimed at improving health outcomes. The rise in healthcare expenditure is driven by factors such as an aging population, chronic diseases, technological advancements in healthcare, high drug prices, and increased service demand. Rising healthcare expenditure boosts access to advanced biologics like Romiplostim for treating chronic conditions such as Immune Thrombocytopenic Purpura (ITP). For instance, in May 2024, the Office for National Statistics reported a 5.6% increase in total healthcare expenditure in the UK from 2022 to 2023, signaling greater investment in healthcare services, including those related to Romiplostim. This trend will support the growth of the nplate, romiplate (romiplostim) market.

A key trend in the nplate, romiplate (romiplostim) market is the development of Nplate for FDA approval to protect adults and children exposed to acute myelosuppressive doses of radiation. Nplate is now being developed for use in radiological or nuclear emergencies, with an administration kit designed to simplify its delivery. For instance, in October 2023, the Biomedical Advanced Research and Development Authority (BARDA) announced support for the development of the Nplate administration kit. This kit aims to simplify the use of Nplate during radiological or nuclear emergencies, with BARDA procuring additional doses of Nplate as part of Project BioShield. Nplate is approved to increase survival rates in both adult and pediatric patients (including newborns) exposed to myelosuppressive doses of radiation, specifically in cases of Hematopoietic Syndrome of Acute Radiation Syndrome (HSARS). This trend is part of the U.S. government’s efforts to enhance preparedness for radiological and nuclear emergencies, which is expected to drive the Nplate, Romiplate (Romiplostim) market.

Major players operating in the nplate, romiplate (romiplostim) market are Novartis AG, Amgen, Intas Pharmaceuticals.

North America was the largest region in the nplate, romiplate (romiplostim) market in 2024. The regions covered in nplate, romiplate (romiplostim) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the nplate, romiplate (romiplostim) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Nplate and Romiplate (romiplostim) are biologic drugs classified as thrombopoietin receptor agonists, used to treat immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, increasing the risk of bleeding. Romiplostim stimulates platelet production in the bone marrow, helping maintain a safe platelet count in patients with chronic ITP.

The primary patient groups for nplate and romiplate (romiplostim) include pediatric, adult, and geriatric patients. This includes children and adolescents diagnosed with conditions such as chronic immune thrombocytopenia (ITP) that require Romiplate treatment. Romiplate stimulates platelet production, making it a crucial therapy for younger patients with low platelet counts. Pediatric patients may need specific dosages and close monitoring due to their developing bodies. It is used for various conditions, including chronic immune thrombocytopenia, chemotherapy-induced thrombocytopenia, and others, and is available through hospital, retail, and online pharmacies.

The nplate, romiplate (romiplostim) market research report is one of a series of new reports that provides nplate, romiplate (romiplostim) market statistics, including the nplate, romiplate (romiplostim) industry's global market size, regional shares, competitors with a nplate, romiplate (romiplostim) market share, detailed nplate, romiplate (romiplostim) market segments, market trends and opportunities, and any further data you may need to thrive in the nplate, romiplate (romiplostim) industry. This nplate, romiplate (romiplostim) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nplate, romiplate (romiplostim) market consists of sales of the lyophilized powder for injection, nplate 500 mcg, and nplate 125 mcg. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.